WO2014207664A3 - Composition pharmaceutique stable d'asénapine - Google Patents
Composition pharmaceutique stable d'asénapine Download PDFInfo
- Publication number
- WO2014207664A3 WO2014207664A3 PCT/IB2014/062575 IB2014062575W WO2014207664A3 WO 2014207664 A3 WO2014207664 A3 WO 2014207664A3 IB 2014062575 W IB2014062575 W IB 2014062575W WO 2014207664 A3 WO2014207664 A3 WO 2014207664A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- asenapine
- pharmaceutical composition
- stable pharmaceutical
- pharmaceutically acceptable
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une composition pharmaceutique stable pour l'administration par voie buccale et/ou sublinguale comprenant de l'asénapine ou un de ses sel pharmaceutiquement acceptable, un antioxydant, un polymère soluble dans l'eau, un diluant soluble dans l'eau, un délitant et éventuellement un ou plusieurs excipients pharmaceutiquement acceptables présentant une biodisponibilité améliorée ou bioéquivalente au produit commercialisé Saphris ®, Sycrest ® et un procédé de préparation de ceux-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2206/MUM/2013 | 2013-06-28 | ||
IN2206MU2013 IN2013MU02206A (fr) | 2013-06-28 | 2014-06-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014207664A2 WO2014207664A2 (fr) | 2014-12-31 |
WO2014207664A3 true WO2014207664A3 (fr) | 2015-04-02 |
Family
ID=52142775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/062575 WO2014207664A2 (fr) | 2013-06-28 | 2014-06-25 | Composition pharmaceutique stable d'asénapine |
Country Status (2)
Country | Link |
---|---|
IN (1) | IN2013MU02206A (fr) |
WO (1) | WO2014207664A2 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170007537A1 (en) * | 2014-02-18 | 2017-01-12 | Hetero Research Foundation | Pharmaceutical compositions of asenapine |
US10085971B2 (en) | 2016-08-22 | 2018-10-02 | Navinta Iii Inc | Pharmaceutical solution of asenapine for sublingual or buccal use |
KR102614709B1 (ko) | 2016-12-20 | 2023-12-18 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템 |
CN110087640A (zh) | 2016-12-20 | 2019-08-02 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
US11033512B2 (en) | 2017-06-26 | 2021-06-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
KR20210022656A (ko) | 2018-06-20 | 2021-03-03 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀을 함유하는 경피 치료 시스템 |
CN109288800A (zh) * | 2018-10-30 | 2019-02-01 | 天津仁生医药科技有限公司 | 马来酸阿塞那平片及其制备方法 |
CN109330984A (zh) * | 2018-11-20 | 2019-02-15 | 天津仁生医药科技有限公司 | 一种马来酸阿塞那平舌下片及其制备方法 |
JP7170124B2 (ja) * | 2019-10-28 | 2022-11-11 | 久光製薬株式会社 | アセナピン-n-オキシドの生成を抑制する方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763476A (en) * | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
WO2012123325A1 (fr) * | 2011-03-11 | 2012-09-20 | Medichem S.A. | Nouvelles formes cristallines du sel de trans-5-chloro-2-méthyl-2,3,3a,12b-tétrahydro-1h-dibenzo[2,3:6,7] oxépino[4,5-c]pyrrole avec l'acide maléique |
-
2014
- 2014-06-25 WO PCT/IB2014/062575 patent/WO2014207664A2/fr active Application Filing
- 2014-06-25 IN IN2206MU2013 patent/IN2013MU02206A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763476A (en) * | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
WO2012123325A1 (fr) * | 2011-03-11 | 2012-09-20 | Medichem S.A. | Nouvelles formes cristallines du sel de trans-5-chloro-2-méthyl-2,3,3a,12b-tétrahydro-1h-dibenzo[2,3:6,7] oxépino[4,5-c]pyrrole avec l'acide maléique |
Also Published As
Publication number | Publication date |
---|---|
WO2014207664A2 (fr) | 2014-12-31 |
IN2013MU02206A (fr) | 2015-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014207664A3 (fr) | Composition pharmaceutique stable d'asénapine | |
WO2010092090A3 (fr) | Nouveaux sels de la sitagliptine | |
WO2013188273A8 (fr) | Composition pharmaceutique ophtalmique topique contenant de l'axitinib | |
WO2009066315A3 (fr) | Compositions à libération prolongée de trimétazidine et procédé de préparation | |
EP3590498A4 (fr) | Préparation, comprenant un complexe d'inclusion de varénicline ou d'un sel pharmaceutiquement acceptable de celle-ci, pour administration par voie orale | |
WO2012135615A3 (fr) | Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci | |
CA2863376A1 (fr) | Comprimes gastro-resistants | |
WO2013188268A8 (fr) | Composition pharmaceutique ophtalmique topique contenant du pazopanib | |
WO2014033526A9 (fr) | Compositions pharmaceutiques d'étoricoxib | |
WO2011141488A3 (fr) | Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone | |
WO2014016754A3 (fr) | Compositions pharmaceutiques d'inhibiteur de la pompe à protons | |
WO2010070677A3 (fr) | Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables | |
WO2015125152A3 (fr) | Compositions pharmaceutiques d'asénapine | |
EP3216450A8 (fr) | Préparation pharmaceutique comprenant un inhibiteur de la cycline et son procédé de préparation | |
WO2010046932A3 (fr) | Composition pharmaceutique de minocycline à libération prolongée et son procédé | |
WO2015002755A3 (fr) | Composés pour le traitement du paludisme | |
WO2014125504A3 (fr) | Compositions pharmaceutiques de fébuxostat | |
WO2010137040A3 (fr) | Nouvelles compositions pharmaceutiques de ranolazine | |
EP3530654A4 (fr) | Composé d'acide carboxylique à substitution quinolinyle ou sel pharmaceutiquement acceptable de celui-ci, composition pharmaceutique et utilisation associées | |
WO2013188279A8 (fr) | Composition pharmaceutique ophtalmique topique contenant du cediranib | |
WO2017034242A3 (fr) | Nouveau dérivé de catéchol et composition pharmaceutique le comprenant | |
WO2017098533A3 (fr) | Procédé de préparation de lisdexamphétamine | |
WO2012108631A3 (fr) | Compositions pharmaceutiques comprenant des nanoparticules qui contiennent du révaprazan et procédés de préparation associés | |
MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
WO2017004172A8 (fr) | Synthèse totale de shishijimicine a et d'analogues de celle-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14817924 Country of ref document: EP Kind code of ref document: A2 |